We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Positive Safety and Efficacy Data Move Off-the-Shelf CAR-T into Registry Trial
Positive Safety and Efficacy Data Move Off-the-Shelf CAR-T into Registry Trial
CRISPR Therapeutics’ off-the-shelf CAR-T treatment conferred clinical benefits similar to those achieved with CAR-T treatments derived from the patients’ own cells, posting a 58 percent overall response and 38 percent complete response rate in a small series of patients with large B-cell lymphoma.